Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
作者信息
Spiegel Jay Y, Dahiya Saurabh, Jain Michael D, Tamaresis John, Nastoupil Loretta J, Jacobs Miriam T, Ghobadi Armin, Lin Yi, Lunning Matthew, Lekakis Lazaros, Reagan Patrick, Oluwole Olalekan, McGuirk Joseph, Deol Abhinav, Goy Andre, Vu Khoan, Andreadis Charalambos, Munoz Javier, Bennani N Nora, Vose Julie M, Dorritie Kathleen A, Neelapu Sattva S, Locke Frederick L, Rapoport Aaron P, Hill Brian T, Miklos David B
机构信息
Stanford University Medical Center, Stanford, CA.
University of Maryland School of Medicine-Greenebaum Comprehensive Cancer Center, Baltimore, MD.
出版信息
Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.
Abstract
摘要
相似文献
1
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.
2
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood. 2020 Jun 4;135(23):2106-2109. doi: 10.1182/blood.2019004162.
3
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
4
[Successfully treatment with axicabtagene ciloleucel of a female patient with an early relapsed diffuse large B-cell lymphoma].
Recenti Prog Med. 2025 Feb;116(2):e33-e35. doi: 10.1701/4450.44452.
5
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
6
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
Oncologist. 2020 Jan;25(1):e138-e146. doi: 10.1634/theoncologist.2019-0395. Epub 2019 Oct 4.
7
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1012-1021. doi: 10.1016/j.ijrobp.2019.05.065. Epub 2019 Jun 5.
8
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):753-759. doi: 10.1016/j.clml.2022.05.004. Epub 2022 May 23.
9
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Future Oncol. 2021 Apr;17(11):1269-1283. doi: 10.2217/fon-2020-0291. Epub 2021 Jan 15.
10
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
Blood Adv. 2025 Feb 11;9(3):455-462. doi: 10.1182/bloodadvances.2024012992.
引用本文的文献
1
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.
J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.
2
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.
Cell Transplant. 2025 Jan-Dec;34:9636897251338713. doi: 10.1177/09636897251338713. Epub 2025 Jun 5.
3
Single-cell RNA sequencing in diffuse large B-cell lymphoma: tumor heterogeneity, microenvironment, resistance, and prognostic markers.
Front Oncol. 2025 Apr 9;15:1583250. doi: 10.3389/fonc.2025.1583250. eCollection 2025.
4
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.
Nat Cancer. 2025 Apr 3. doi: 10.1038/s43018-025-00941-2.
5
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.
Nat Med. 2025 Apr;31(4):1183-1194. doi: 10.1038/s41591-025-03532-x. Epub 2025 Apr 1.
6
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL.
Cancer Immunol Immunother. 2025 Mar 22;74(5):156. doi: 10.1007/s00262-025-04001-7.
7
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.
Target Oncol. 2025 Mar;20(2):217-234. doi: 10.1007/s11523-025-01133-9. Epub 2025 Mar 4.
8
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.
Nat Rev Clin Oncol. 2025 Apr;22(4):241-261. doi: 10.1038/s41571-025-00992-5. Epub 2025 Feb 18.
9
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies.
J Immunol Res. 2025 Jan 15;2025:5845167. doi: 10.1155/jimr/5845167. eCollection 2025.
10
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044.
本文引用的文献
1
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13.
2
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
Haematologica. 2021 Apr 1;106(4):978-986. doi: 10.3324/haematol.2019.238634.
3
Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
Biol Blood Marrow Transplant. 2019 Nov;25(11):e344-e351. doi: 10.1016/j.bbmt.2019.06.036. Epub 2019 Jul 4.
4
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
5
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
6
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
Zotero 插件